Adovate

Grateful for Acumen Pharmaceuticals, Inc. and Daniel O'Connell for their continued efforts in advancing human health and keeping Charlottesville on the map in this important fight!

I am about to wrap up my first attendance to the BioHealth Capital Region Forum and Investor Conference. Thank you to Richard Bendis, Andy Eckert, M.S., Brett Shealy, John Newby and others for putting on this incredible event to bring the #DMV #biotech community together. The team at Adovate is thrilled to be part of this rapidly growing ecosystem. The presence of Gov. Wes Moore and Gov Glenn Youngkin further highlights the ongoing investments being made to support this vital sector. Thank you to everyone who is supporting Adovate's mission to improve patient care worldwide. #vabio #biopharma #biotech

Meet us at #BIO2024! Exciting developments at Adovate! As a pioneering pharmaceutical company, we're dedicated to creating best-in-class, novel drug candidates. Our focus? Adenosine receptors—a key player in major diseases like #asthma, #cancer, and #diabetes. Using our advanced adenosine drug development platform, we are designing and producing groundbreaking compounds with superior characteristics.

Adovate was named as a recipient of a Virginia Catalyst grant award. This grant is to fund the Phase 2 human studies in asthma patients of our lead compound, ADO-5030.? Thank you to our collaborators and world-leading researchers Dr. Larry Borish at the University of Virginia, and Dr. Liwu Li at Virginia Tech. We are excited to continue our work with them on this important program to develop an effective treatment for the 30-50% of asthma patients that are unresponsive to steroids, the current first-line therapy, as well as being a potential treatment for all asthma patients. A link to the press release is attached. #Adovate #VirginiaCatalyst #GrantAward #Biosciences #Innovation #Healthcare #asthma #Research #EconomicGrowth #Collaboration #UVA #VirginiaTech?

Happy New Year! #2024 #happynewyear #Adovate